Skip to content

Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study

Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02100592
Enrollment
8
Registered
2014-04-01
Start date
2012-10-31
Completion date
2014-03-31
Last updated
2014-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injury

Keywords

brain injury, coma, intensive care, early rehabilitation

Brief summary

Severe brain injuries induce alteration of state of consciousness. These functional limitations can be significantly alleviated by treatment neurorehabilitation, particularly if this is established early. It has been shown that treatment of vertical integration in patients in a vegetative state or minimally conscious state can improve the level of supervision and positive influence on rehabilitation. Therefore, there are sufficient indications that anticipate the treatment of vertical integration, since the phase of hospitalization in ICUs, may improve the functional outcome of the patient.

Detailed description

Early verticalization and stepping with the equipment Hocoma Erigo, during monitoring of vital parameters. The device Erigo is already CE marked and, for the purposes of the study, will be used in accordance with the intended use of the same mark (after-market clinical investigation).

Interventions

OTHEREarly rehabilitation treatment on Erigo Hocoma

5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °

Sponsors

Ospedale Generale Di Zona Moriggia-Pelascini
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patient / a severe acquired brain injury occurred 3 to 30 days prior to enrollment 2. Age between 18 and 75 years 3. Glasgow Coma Scale ≤ 8 at entrance in ICUs 4. Adequate respiratory exchange with PaO2/FiO2 ≥ 250 5. Absence of sedation increased

Exclusion criteria

1. Major chest trauma with multiple rib fractures and / or pneumothorax 2. Presence of fractures, vascular lesions, skin lesions with loss of substance in the abdomen, pelvis or lower limb 3. Cardiovascular instability despite support with amines 4. Intracranial pressure (ICP)\> 25 mm / Hg 5. Cerebral Perfusion Pressure (PPC) \<60 mm / Hg 6. Severe kidney failure requiring replacement therapy 7. Decompensated liver disease 8. Hematocrit value of ≤ 30% 9. Body weight\> 135 kg or height\> 210 cm 10. Deep vein thrombosis

Design outcomes

Primary

MeasureTime frameDescription
Adverse events during verticalization21 days: from T1 (first session) to T15 (last session)It is a composite outcome, assessing the occurence of at least one of the following conditions (component outcomes): Heart rate \<40 bpm or\> 150 bpm; Mean arterial pressure \<70 mmHg; Arterial oxygen saturation \<90%; Onset of ECG anomalies; Traumatic dislodgement of a device;

Secondary

MeasureTime frameDescription
Changes of hemodynamic parameters21 days: from T1 (first session) to T15 (last session)Changes of hemodynamic parameters during each session and from T1 to T15; assessed parameters are: stroke volume; peripheral resistances; mean arterial pressure; cerebral perfusion pressure.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026